Indeed, azithromycin, frequently used in asthmatic children with lower respiratory tract infection, inhibits the accumulation of neutrophils in pulmonary airways by affecting interleukin-17 downstream signal, and by inhibiting the release of neutrophil mobilizing cytokines: macrophage inflammatory protein-2(MIP-2), CXC chemokine ligand-5(CXCL-5), and granulocyte macrophage colony-stimulating factor(GM-CSF) (43). The gene discussed is CSF2; the disease is Recurrent lower respiratory tract infections.